BLRX - バイオラインRx (BioLineRx Ltd.) バイオラインRx

 BLRXのチャート


 BLRXの企業情報

symbol BLRx
会社名 BioLineRx Ltd (バイオラインRx)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種    医療関連(Health Care)
概要 事業概要 --   バイオラインRXはイスラエルのバイオ医薬品メ―カ―。中枢神経系疾患、感染性疾患、心臓血管疾患、自己免疫疾患などの治療法の開発に焦点を置く。急性心筋梗塞、急性骨髄性白血病、セリアック病、良性皮膚腫瘍、炎症性腸疾患、C型肝炎ウイルスなどの臨床段階治療薬候補を保有する。   BioLineRx Ltd. is a clinical stage biopharmaceutical company focused on oncology. The company was founded in April 2003 and is headquartered in Modi'in, Israel.
本社所在地 2 HaMa'ayan Street Modi'in 7177871 ISR
代表者氏名
代表者役職名
電話番号
設立年月日 37712
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 48人
url www.biolinerx.com
nasdaq_url https://www.nasdaq.com/symbol/blrx
adr_tso 83425172
EBITDA EBITDA ー
終値(lastsale) 1.27
時価総額(marketcap) 105949968.44
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 BLRXのテクニカル分析


 BLRXのニュース

   BioLineRx Reports Second Quarter 2020 Financial Results and Provides Corporate Update  2020/08/06 11:00:00 PR Newswire
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial…
   BioLineRx (BLRX) to Report Q2 Earnings: What's in the Cards?  2020/07/24 17:08:05 Yahoo Finance
BioLineRx (BLRX) will provide updates on its clinical programs when it releases second-quarter 2020 results.
   BioLineRx Reports Year-End 2019 Financial Results and Provides Corporate Update  2020/03/12 11:00:00 PR Newswire
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial…
   BioLineRx's Pancreatic Cancer Drug Gets Orphan Drug Tag in EU  2020/01/15 14:56:00 Zacks Investment Research
The European Commission bestows an orphan drug status on BioLineRx's (BLRX) lead candidate Motixafortide, currently being evaluated with Merck's Keytruda to treat pancreatic cancer. Stock up.
   BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe  2020/01/14 12:00:00 PR Newswire
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today announced that the European…
   BioLineRx Reports Second Quarter 2020 Financial Results and Provides Corporate Update  2020/08/06 11:00:00 PR Newswire
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial…
   BioLineRx (BLRX) to Report Q2 Earnings: What's in the Cards?  2020/07/24 17:08:05 Yahoo Finance
BioLineRx (BLRX) will provide updates on its clinical programs when it releases second-quarter 2020 results.
   BioLineRx Reports Year-End 2019 Financial Results and Provides Corporate Update  2020/03/12 11:00:00 PR Newswire
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial…
   BioLineRx's Pancreatic Cancer Drug Gets Orphan Drug Tag in EU  2020/01/15 14:56:00 Zacks Investment Research
The European Commission bestows an orphan drug status on BioLineRx's (BLRX) lead candidate Motixafortide, currently being evaluated with Merck's Keytruda to treat pancreatic cancer. Stock up.
   BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe  2020/01/14 12:00:00 PR Newswire
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today announced that the European…
   BioLineRx Reports Second Quarter 2020 Financial Results and Provides Corporate Update  2020/08/06 11:00:00 PR Newswire
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial…
   BioLineRx (BLRX) to Report Q2 Earnings: What's in the Cards?  2020/07/24 17:08:05 Yahoo Finance
BioLineRx (BLRX) will provide updates on its clinical programs when it releases second-quarter 2020 results.
   BioLineRx Reports Year-End 2019 Financial Results and Provides Corporate Update  2020/03/12 11:00:00 PR Newswire
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial…
   BioLineRx's Pancreatic Cancer Drug Gets Orphan Drug Tag in EU  2020/01/15 14:56:00 Zacks Investment Research
The European Commission bestows an orphan drug status on BioLineRx's (BLRX) lead candidate Motixafortide, currently being evaluated with Merck's Keytruda to treat pancreatic cancer. Stock up.
   BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe  2020/01/14 12:00:00 PR Newswire
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today announced that the European…

 関連キーワード  (― 米国株 バイオラインRx BLRX BioLineRx Ltd.)

 twitter  (公式ツイッターやCEOツイッターなど)